Movement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan

Market Focus

05/29

On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.

On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.

The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1142232953"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142232953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142232953?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 13:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142232953","market":"us","top_or_hot":-1,"title":"Movement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan","media":"Market Focus","content":"<p><p>On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.</p><p>On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.</p><p>The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CanNova Bio Rises 10.01% in Regular Trading, Receives First-Time Buy Rating from Shenwan Hongyuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 13:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.</p><p>On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.</p><p>The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1142232953","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142232953","pubTimestamp":1780034063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"动静提示|康诺生物常规交易涨10.01%获申万宏源首次买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On May 29, CanNova Bio rose 10.01% in regular trading, trading at HK$63.2 per share, with trading volume of HK$112 million.On the news front, Shenwan Hongyuan Securities initiated coverage on CanNova Bio with a Buy rating and a target price of HK$89.47, implying 48% upside. The research report highlighted that the core product Sipuqibai monoclonal antibody has received approval for three indications, all of which have been included in the National Medical Insurance Directory. Drug sales revenue reached RMB 315 million in 2025, representing a 776% year-over-year increase. Additionally, the company's NewCo partner was acquired by Gilead Sciences, entitling CanNova Bio to receive approximately US$250 million in upfront payments.The broader biotech sector rallied on the same day, with Innovent Bio up 12.29%, 3SBio up 9.04%, Akeso up 8.15%, and Remegen up 6.21%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}